CD33-TIM3 tandem CAR T cells

CD33-TIM3 tandem CAR T cells are an experimental, preclinical-stage cellular immunotherapy being investigated for the treatment of Acute Myeloid Leukemia (AML). This dual-targeting chimeric antigen receptor (CAR) T cell therapy simultaneously targets two myeloid-associated antigens: CD33, which is overexpressed in the majority of AML cases, and T-cell immunoglobulin and mucin-domain containing-3 (TIM3), which is expressed on leukemic stem cells but absent on healthy hematopoietic stem cells. The tandem CAR format links both antigen-binding domains (scFvs) in a single CAR construct, aiming to enhance binding avidity and cytotoxicity against dual-antigen-expressing AML cells while potentially sparing healthy tissues. Developed by researchers at LMU Munich, this construct is being evaluated as a potential bridge-to-transplant therapy to achieve deeper remissions in AML patients.

Other names

CD33-TIM3 dual CAR T cellsCD-33-TIM3 dual CAR T cellsCD 33-TIM3 dual CAR T cellsCD33-TIM3 tandem CAR TCD-33-TIM3 tandem CAR TCD 33-TIM3 tandem CAR T